BNT327 Dose Level 1 (DL1)

Phase 2

BioNTech SE (BNTX)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

BNTXPhase 2$25.2B

BNT327 Dose Level 1 (DL1) Phase 2 Est. Readout

BNT327 Dose Level 1 (DL1)• Extensive-stage Small-cell Lung Cancer110

Jun 2027~Confirmed

CT.gov

00%

Competitive Landscape

1 competitor in Extensive-stage Small-cell Lung Cancer

View Full Landscape

Drug Information

Target Indication

Extensive-stage Small-cell Lung Cancer

Clinical Trial

NCT06449209

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BNTX

BioNTech SE

Biological Products, (No Diagnostic Substances)•Europe•NASDAQ

Related Pipeline

BNT113Phase 3

Unresectable Head and Neck Squamous Cell Carcinoma

BNT162b1Phase 3

SARS-CoV-2 Infection

PumitamigPhase 3

Extensive-stage Small-cell Lung Cancer

BNT162b2Phase 3

SARS-CoV-2 Infection

BNT162b2 OMIPhase 3

SARS-CoV-2 Infection

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts